Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (791-800 of 831) with videos related to

Pageof 84
Sort By:
The Lancet. Oncology|July 31, 2025
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomasNorbert Galldiks, Philipp Lohmann, Mariam Aboian, et al.
Neuro-Oncology|February 14, 2022
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effortEmilie Le Rhun, Patrick Devos, Sebastian Winklhofer, et al.
Cell Reports. Medicine|March 18, 2026
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomasYouri Hoogstrate, Santoesha A Ghisai, Levi van Hijfte, et al.
Neuro-Oncology|October 5, 2021
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysisYouri Hoogstrate, Santoesha A Ghisai, Maurice de Wit, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Cell Reports. Medicine|June 21, 2023
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomasMarkus Bredel, Lluís Espinosa, Hyunsoo Kim, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Pageof 84

Showing results (791-800 of 831) with videos related to

Sort By:
Pageof 84
The Lancet. Oncology|July 31, 2025
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomasNorbert Galldiks, Philipp Lohmann, Mariam Aboian, et al.
Neuro-Oncology|February 14, 2022
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effortEmilie Le Rhun, Patrick Devos, Sebastian Winklhofer, et al.
Cell Reports. Medicine|March 18, 2026
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomasYouri Hoogstrate, Santoesha A Ghisai, Levi van Hijfte, et al.
Neuro-Oncology|October 5, 2021
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysisYouri Hoogstrate, Santoesha A Ghisai, Maurice de Wit, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Cell Reports. Medicine|June 21, 2023
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomasMarkus Bredel, Lluís Espinosa, Hyunsoo Kim, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Pageof 84